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Abstract
It is 20 years since the identification of PKD1, the major gene mutated in autosomal dominant 
polycystic kidney disease (ADPKD), followed closely by the cloning of PKD2. These major 
breakthroughs have led in turn to a period of intense investigation into the function of the two 
proteins encoded, polycystin-1 and polycystin-2 and how defects in either protein lead to cyst 
formation and non-renal phenotypes. In this review, we summarise the major findings in this area 
and present a current model of how the polycystin proteins function in health and disease.
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Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is the fourth ranked cause of 
kidney failure and the most common inherited nephropathy. Beyond the kidney, the major 
organs affected include the liver, pancreas, heart and intracerebral arteries. Although long 
considered an untreatable disease, the availability of new treatments that could alter its 
natural history are becoming a reality1, 2.
Mutations in two genes, PKD1 and PKD2, cause ADPKD, with the existence of ‘PKD3’  in 
doubt following reanalysis of the reported unlinked cases3. In typical renal clinic 
populations, PKD1 accounts for 80-85% of cases with PKD2 accounting for the remainder. 
Although PKD1 and PKD2 patients have overlapping renal and extra-renal features, 
truncating PKD1 mutations are associated with the poorest renal survival whereas PKD2 
mutations have the best outcomes; non-truncating PKD1 mutations display an intermediate 
spectrum4.
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PKD1 and PKD2 encode the proteins, polycystin-1 (PC1) and polycystin-2 (PC2), 
respectively 5. Early studies showed that tissue expression of both proteins was largely 
overlapping although not identical6, 7. In addition, Pkd2 expression appeared more constant 
while that of Pkd1 was developmentally regulated8. Biochemical studies indicate that both 
proteins interact to form a polycystin (PC) complex9-11. However this needs to be reconciled 
with the non-overlapping subcellular location/s of both proteins, especially the predominant 
localisation of PC2 in the ER12 where it may function as a Ca2+ release channel13-15.
ADPKD disease mechanism
There is agreement that ADPKD is associated with loss of function; null Pkd1 or Pkd2 
mouse models are lethal and develop cysts by ~E13.516, 17. Disagreement has centred on 
whether a complete loss of the normal allele is required (two hit hypothesis) or whether 
cysts can develop once the level of function protein falls below a specific level (threshold 
hypothesis)18. Consistent with the need for two hits, inactivating and base pair somatic 
mutations have been identified in ADPKD renal and liver cystic epithelium, and cysts are 
clonal and so may be derived from a single cell19-21. The hypermutable Pkd2 allele (WS25), 
develops cysts following spontaneous loss of the normal allele22 and induced mutation in 
conditional models shows that loss of the second allele causes cystogenesis. However, the 
timing of this event significantly influences disease severity; before P13, cysts rapidly 
develop, while later loss results in slowly progressive disease23, 24. The timing of somatic 
mutation thus significantly influences growth rates, possibly due to the basal level of 
proliferation or a critical developmental window. Somatic mutation could explain the focal 
nature of cyst development, found in a limited number of nephrons. It has also been 
suggested that PKD1 is a more severe disease than PKD2 due to PKD1 being a larger 
mutational target25.
On the other hand, hypomorphic models indicate that cysts can develop even if low levels of 
normal PC1 (15-20%) are present26, 27 and cysts in Pkd1+/+; Pkd1−/− chimeric mice initially 
comprise cells of both genotypes, only later (and associated with histological changes) being 
all Pkd1−/−28. PKD2 somatic mutations in PKD1 cysts and vice versa29, 30, plus other 
karyotypic changes in developing cysts31 also indicate complexity in cyst development, 
rather than due simply to the loss of both alleles18.
A threshold model of cystogenesis in ADPKD
The data presented above and recent evidence that different types of PKD1 mutation 
(truncating and non-truncating) are associated with different disease severity4, that humans 
and mice with two incompletely penetrant alleles can be viable (severe to typical disease), 
and that in utero onset ADPKD can be due to biallelic PKD1 or PKD2 mutations 
(inactivating plus hypomorphic or two hypomorphic)32-36 suggests that a threshold or 
dosage model best explains cystogenesis in ADPKD (Figure 1). In patients with a 50% 
reduction of functional PC1 or PC2 (typical patients with an inactivating mutation), cysts 
can occur if the level of functional PC falls below the cystogenic threshold. This may occur 
by somatic mutation to the other allele, but stochastic cellular variability of expression of the 
remaining ADPKD allele37, 38 and other factors, such as renal damage (which has been 
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shown to promote cystogenesis in mice), may determine if a cyst develops39, 40. It is 
possible that this minimum threshold itself could vary between animals, by nephron 
segment, developmental stage, tissue and even cell type23, 41, 42. In mice, slowly progressive 
disease occurs if the level of functional PC1 is ~40%, but rapidly progressive disease occurs 
with ~20% functional PC1, highlighting the influence of dosage36 (Figure 1). Since the level 
of functional PC seems linked to renal disease severity, treatments that can promote that 
level may help to slow disease progression.
Once initiated, further genetic events at the disease locus and elsewhere, similar to tumour 
development in cancer, plus other environmental influences, may favour growth and survival 
of a cyst. Of note, even in hypomorphic models, cyst development is focal36 suggesting that 
factors in addition to the level of the functional protein are important but that once tipped 
into a cystogenic cascade, possibly irreversible. In conditional knockouts with low levels of 
induced deletion of the normal allele during adulthood, cyst development is slow but later 
cysts cluster around early ones, indicating that paracrine cystogenic factors may diffuse from 
developed cysts, although the non-randomness of Cre-inactivation should also be 
considered 43.
Mutation to the transcription factor HNF1B leads to a diverse range of kidney phenotypes 
including renal agenesis, dysplasia and renal malformations but most commonly cysts, 
occasionally phenocopying ADPKD as the Renal Cystic and Diabetes Syndrome (RCAD)44. 
Both PKD2 and PKHD1, the autosomal recessive PKD (ARPKD) gene, are under the 
transcriptional control of HNF1B45, and a combination of PKD1 and HNF1B pathogenic 
alleles may cause in utero onset PKD 34. This may be the result of the combination of 
altered regulation of HNF1B targets and the PKD1 mutation.
The microRNA-17 (miRNA17) binds to the 3 ?UTR of PKD2 and regulates the stability of 
PKD2 mRNA and its translation. Transgenic overexpression of miRNA17 leads to a cystic 
phenotype in Xenopus and mice, through down-regulating Pkd2 mRNA, confirming the 
importance of gene dosage46. A transgenic model with two miRs targeting Pkd1 also 
resulted in a slowly progressive PKD model47. The RNA-binding protein, Bicaudal C 
(Bicc1), is mutated in several mouse models of PKD (bpk, jcpk) and competes with 
miRNA17 for binding to Pkd2 mRNA: Pkd2 levels are reduced with Bicc1 mutation48.
Disease mechanisms in non-renal tissues
A striking finding from Pkd1 and Pkd2 null animals is the uniform lack of liver cysts, 
common pancreatic cysts and variable expression of vascular abnormalities16, 17, 49. These 
findings indicate that each tissue may have a different threshold for disease onset and 
expression. An unusual feature of the liver phenotype is the strong female predisposition to 
develop polycystic liver disease50. This is the converse of the modest male predisposition to 
develop larger polycystic kidneys 25 and earlier ESRD 4, which implies different modifiers 
of this phenotype.
The prevalence of intracranial aneurysms (ICA) in ADPKD varies between 6-16% with 
evidence of familial clustering51, 52. ICA rupture can occur in younger individuals and 
before the onset of hypertension, suggesting a primary link between ICA formation and 
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polycystin function53, 54. ICAs have been reported in only a few Pkd1 mice and these have 
tended to be hypomorphic, transgenic or challenged heterozygous animals55-57 rather than 
vascular-specific knockouts58. These findings suggest that gene dosage is important in the 
genesis of ICAs but that disease penetrance is determined by other factors such as genetic 
background and environmental ‘ stress’ . An early predisposing factor could be endothelial 
dysfunction, detected in resistance arteries of normotensive non-cystic heterozygous mice59.
A common polycystin pathway for cystogenesis
Genetic interaction between cystogenes
Consistent with a dosage model of ADPKD cystogenesis, human and mouse studies have 
shown genetic interaction between cystogenes (Figure 2). Contiguous deletion of PKD1 and 
the adjacent tuberous sclerosis gene (TSC2) results in much more severe PKD than a PKD1 
or TSC2 mutation alone60, 61. The mechanism may be related to overlap between their 
downstream signalling pathways involving mTOR and possibly others62, 63, but a direct 
interaction between PC1 and the TSC2 protein, tuberin, may also be relevant64.
Early-onset PKD foetuses with co-inheritance of mutations in PKD2 and PKHD1 have also 
been reported, suggesting another potential genetic interaction34 (Figure 2). The ARPKD 
protein, fibrocystin (FPC), may bind to PC2 and regulate its Ca2+ permeability65. Genetic 
studies in mice have also shown a genetic interaction between Pkd1 and Pkhd141. In one 
family, patients with digenic PKD1 and PKD2 mutations had ESRD ~20 years earlier than 
single mutations to either gene66, 67 and digenic mouse studies with hypermutable (Pkd2) 
and hypomorphic (Pkd1) alleles showed a similar dose dependent, synergistic phenotypic 
enhancement68.
Studies of conditional kidney inactivation of polycystic liver disease (PCLD) genes (Prkcsh, 
Sec63) or Pkhd1 with the ADPKD genes provide further evidence of cystogenic interaction 
and a dosage dependence of Pkd1, where the level of PC1 plays a central role41 (Figure 2). 
In this model, Pkd2 cannot substitute for Pkd1 but is required for Pkd1 function suggesting 
that the PC1-PC2 complex is essential. In PCLD, the disease proteins are involved in 
glycosylation or translocation of membrane proteins into the ER, plus ER quality 
control69, 70 and hence, involved with processing the large and complex PC1 or PC2. It is 
not clear if PLCD is restricted to the liver because this organ is more dosage sensitive for 
these proteins or if somatic mutations occur more frequently in the liver41.
Polycystin structure and function
Polycystin-1
The 3D structure of PC1 remains unresolved and continues to prove challenging in view of 
the size, and complexity of the protein. Nonetheless, the modular domain structure of the 
protein has stimulated study of isolated domains. Figure 3 depicts our current view of the 
structure of the protein.
The GAIN domain—A major advance has been the crystallisation of the GPCR-
Autoproteolysis Inducing (GAIN) regulatory domain71, a 320 residue region which includes 
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the 50 residue G protein-coupled receptor proteolysis site (GPS) motif which mediates cis-
autoproteolysis of PC1 to generate a 320kDa (unglycosylated) N-terminal product (NTP) 
and a 140kDa C-terminal product (CTP) which remain non-covalently bound72. The GAIN 
domain is evolutionarily conserved and found in all 33 cell-adhesion GPCRs, orphan 
receptors with no known ligands, as well as all 5 PC1-like proteins71 (Figure 3). The 
functional role of this cleavage is not clear but may be a mechanism of stabilising protein 
folding and hence trafficking. An unanswered question is whether the uncleaved form of 
PC1 is functional since the extent of cleavage of the endogenous protein varies in different 
cells. A Pkd1 GPS cleavage mouse mutant (Pkd1v/v, T3041V) escapes embryonic lethality 
but develops rapidly progressive post-natal PKD72, suggesting a role for the uncleaved form 
during development. The interaction of PC1 with PC2 has been suggested as required for 
efficient GPS cleavage73. However, recent data indicates that PC1 is efficiently cleaved even 
in Pkd2 null cells and in mutant PC1 with the C-tail deleted68, 74. An abundant, surface 
expressed cleaved NTP, detached from the CTP, of unknown function has been reported75.
The PKD domain—An extracellular region that comprises 30% of PC1 (16 copies) is the 
Polycystic Kidney Disease (PKD) domain, which has similar topology to Ig-like and 
fibronectin type III domains76. The first PKD domain is separated from the other 15, which 
exist in tandem (Figure 3). This arrangement of tandem Ig-like domains is reminiscent of 
proteins with structural and mechanical roles such as titin, fibronectin and NCAM. PKD 
domains have been identified in surface layer proteins of some archaeobacteria where they 
may mediate the formation of multicellular structures. The crystal structure of a 
Methanosarcina PKD domain shows the highest similarity to the NMR structure of PKD 
domain 1, revealing its possible role in evolution from unicellular to multicellular 
organisms77.
Biophysical studies have shown that the PC1 extracellular domain is highly extensible 
through the folding and unfolding of the PKD domains78, 79. In addition, the PKD domains 
(human and archae) appear to be stabilised by force-induced formation of a stable 
intermediate state80. These studies are consistent with a role for PC1 in mechanical coupling 
between cells, e.g. in maintaining normal tubular lumen diameter under flow. Indeed, a 
functional role for the PC1 extracellular domains (including the PKD domains) in mediating 
cell adhesion and/or cell junction formation has been demonstrated in mammalian cells from 
several species81-83, likely via trans-homophilic interactions of the PKD domains and cis-
heterophilic interactions with E-cadherin81.
The PLAT domain—The Polycystin-1 Lipoxygenase Alpha-Toxin (PLAT) domain is 
considered a signature domain of the PC1-like proteins84, 85 (Figure 3), and is identified in 
over 1000 different proteins. The PLAT domain crystal structure determined from murine 
Rab6-interacting protein 1 (Rab6IP1) and white sea coral 11R-lipooxgenase86, 87 show a Ś
sandwich with two sheets of four strands each. Sequence homology to PC1 PLAT is 
however low (20%). Genetic studies of LOV-1, the C.elegans PC1 homologue, have 
implicated PLAT in mediating male mating behaviour in worms88, but the domain structure 
and function of worm and human PC1 are clearly divergent. Recent NMR studies of human 
PC1 PLAT show discrete binding motifs to acidic phospholipids and Ca2+ and that it is 
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phosphorylated (Ong ACM, submitted). It is likely that PC1 PLAT functions as a lipid/
protein binding scaffold to integrate cell signalling and PC1 trafficking.
The C-terminal tail—The best studied region of PC1 is the ~200aa C-terminal tail 
although its 3D structure is still unknown. This contains several functional motifs including 
a coiled-coil domain (aa4220-4251) which mediates binding to PC2 and a G-protein binding 
and activation sequence (aa4111-4184) for heterotrimeric G proteins. It can be 
phosphorylated in vitro and has been shown to bind protein phosphatases which regulate 
PC1 and PC2 phosphorylation 89, 90. Other key signalling proteins or effectors (eg. mTOR, 
Wnt, Jak/Stat) may be similarly regulated 91-93 (see below).
Polycystin-2
A strong body of evidence indicates that PC2 functions primarily as a high conductance non-
selective Ca2+ permeable channel 13, 94, 95 and specific missense mutations (eg D511V) 
abolish Ca2+ permeability in the mutant protein 13, 14. Sequence homology to other TRP 
channels supports this hypothesis: PC2 is also known as TRPP2 96. What is less clear is 
where its primary site of action resides (or whether there are multiple sites of action) and 
whether channel opening is directly regulated by PC1, Ca2+ binding (via its EF-hand) and/or 
phosphorylation (see below). However it is predicted that mutation of either PKD1 or PKD2 
leads to lower cytoplasmic Ca2+ concentrations (reduced entry and/or release) resulting in 
dysregulated cAMP levels and downstream signalling 97.
A second coiled coil domain (CC2)—A second coiled coil domain (CC2) distal to the 
original, CC1, mediates oligomerisation of the PC2 C-terminus (CT2) (to form dimers or 
trimers), an event essential for recognition and binding of the PC1 C-terminus (CT1) to form 
a functional PC1/PC2 protein complex14, 98 (Figure 3). The binding region in CT1 involves 
the coiled coil domain, although the precise stoichiometry of the complex is still debated.
Other oligomerisation motifs—Native PC2 forms higher order oligomers (tetramers, 
others) consistent with the likely tetrameric structure of other TRP channels 11, 99. An N-
terminal dimerization motif and a single cysteine residue (C632), which mediates disulphide 
bonding, likely contribute to the formation of PC2 tetramers100,101.
EF-hand—Invertebrate PC2 homologues have two canonical EF hands (EF1, EF2), 
whereas vertebrate homologues have a single functional Ca2+ binding motif (EF2) due to a 
4aa deletion in the Ca2+ binding loop of EF1102. The functional effect of Ca2+ binding may 
favour monomer over dimer formation103 and/or regulate certain Ca2+ dependent 
interactions, rather than directly impact channel open probability104.
Membrane targeting motifs—The detection of discrete ciliary and plasma membrane 
(PM) pools of PC2 has led to a search for distinct targeting signals for each compartment. 
Conserved ciliary targeting (6RVxP9) and PM (572KxxxF576) export motifs have been 
reported105, 106. Mutation of the RVxP motif does not abolish localisation of PC2 to nodal 
cilia or its function in left-right determination 107 but the functionality of the KxxxF motif 
has not been tested in vivo. It has been postulated that PC2 could be directed from the cis-
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Golgi without transversing the trans-Golgi to the cilia or PM, independently of PC1106. Two 
different PC1 sequences (aa4296-4302; aa4100-4204) have been proposed as required for 
ciliary localisation by heterologous expression108, 109. Several other pathways have been 
reported to regulate the surface expression of mammalian PC2. These include GSK3, PKA 
and CAMK-dependent pathways90, 110, 111. However, it is not known if these signals are 
independent of PC1 or the targeting motifs reported.
Post-translational modification
Phosphorylation and Dephosphorylation
Although multiple phosphorylated residues have been identified from MS analysis, 
functional evidence for a regulatory role is limited. The best evidence comes from studies of 
five serine residues (S76, S80, S801, S812, S829) in PC2, each phosphorylated by a 
different kinase (GSK3, PrKD1, CK2, PKA)90, 110, 112, 113. These appear to regulate a 
number of key steps such as forward and retrograde trafficking, surface localisation, Ca2+ 
permeability and Ca2+ regulation of PC290, 110, 112-114. An important link to PC1 was the 
striking finding that S829, a PKA activated site in PC2, remains constitutively 
phosphorylated in the absence of PC190. The mechanism appears due to loss of protein 
phosphatase-1 action (PP1 binds to CT1)89, 90. PC1 is reported to bind to several receptor 
tyrosine phosphatases but it is unclear whether endogenous PC1 or PC2 are substrates for 
tyrosine kinases115.
The NEK8 kinase is mutated in patients with nephronophthisis (NPHP9), in the spontaneous 
jck cystic mouse and the Lewis polycystic kidney (lpk) rat116-118. In jck kidneys, PC2 
appears to be hyperphosphorylated119. NEK8 is known to act on other substrates such as 
ANKS1 but there is no evidence yet that PC2 is a substrate120.
Ubiquitination and proteosomal degradation
Both PC1 and PC2 are subject to ubiquitin-dependent proteosomal degradation through the 
binding of different E3 ubiquitin ligases, Siah-1 and TAZ121, 122. Taz mutant mice develop 
predominant glomerular cysts and are associated with lower PC2 levels123. Nek1 in turn has 
been shown to phosphorylate TAZ leading to its degradation and increased PC2 levels, 
possibly leading to cystogenesis124. TAZ is known to mediate both Hippo signalling and 
canonical Wnt responses through regulating the degradation of Ś-catenin125. ER associated 
degradation (ERAD) of PC2 can be regulated by PRKCSH 126, 127. These pathways may be 
especially important during nephrogenesis where the dosage of both proteins is critical for 
tubular elongation or in the adult kidney for appropriate repair following injury 128, 129.
PC1 proteolytic cleavage
Additional CT1 cleavage (following GPS cleavage) generating two CT1 cleavage products 
(CCP) of differing length (17, 34 kDa) may occur130, 131 with these products acting as co-
activators of several transcriptional pathways (Stat, Wnt, CHOP), independent of the 
NTP130, 131. A third reported cleavage event generating a P100 CCP might regulate store-
operated Ca2+ entry independently of PC2 through inhibiting translocation of the ER Ca 
sensor STIM-1132.
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Is ADPKD a ciliopathy?
Accumulated data over the past 15 years has implicated functional defects in primary cilia in 
ADPKD pathogenesis but there is also conflicting information133.
Primary cilia involved in PKD
Most cell types have a primary cilium whose role is sensory/mechanosensory. The cilium is 
rooted in the basal body and has a specific mechanism, intraflagellar transport (IFT), for 
distributing proteins anterograde and retrograde, which is essential for cilia formation and 
resorption134. The cilium is a partially separate compartment with the transition zone and 
transition fibers acting as a ciliary gate. In epithelial cells, the cilium extends from the apical 
surface into the tubule lumen. Cilia are essential for certain developmental signaling 
pathways, most notably sonic hedgehog (Shh), and mechanosensory functions, like detecting 
flow; functional cilia are essential for normal development135.
The initial evidence that PKD (ADPKD) is a ciliopathy came from the determination that 
homologous proteins to PC1 (lov1) and PC2 (pkd2) in C. elegans are localized to sensor 
cilia and loss of either results in defective mating behaviour136, 137. Next, a mouse model 
defective for the IFT protein, IFT88, was found to develop PKD138, 139. Subsequently, both 
PC1 and PC2 were localized to cilia in mammalian cells140, 141; recent data has emphasized 
this localization and interaction of these proteins in cilia68, 74. Another study showed that 
knocking out Kif3A (an IFT motor subunit) in the collecting duct resulted in PKD in this 
segment142. While structural cilia abnormalities are found in some ciliopathies, including 
ARPKD143, cilia from Pkd1 or Pkd2 mutations were considered normal. Recently, study of 
the Pkd1RC/RC and Pkd1RC/null hypomorphic models has revealed longer cilia, with cilia 
length associated with the level of functional PC136. It is unclear if the length difference is 
directly associated with the reduced level of PC1 or compensation for reduced cilia 
signalling144.
Recessively inherited developmental disorders with renal defects from PKD to 
nephronophthisis (NPHP), Meckel syndrome (MKS), Joubert syndrome (JBTS) and Bardet 
Biedl syndrome (BBS) are ciliopathies135. The cilia link includes localization of the proteins 
to the transition zone, other regions of the cilia, the basal body or to a protein complex 
termed the BBSome shown to be important for localizing membrane associated proteins to 
the cilium145, 146. Cilia in these mutants have altered protein composition. Many of the 
extra-renal phenotypes observed in these disorders are also consistent with ciliary defects: 
retinal defects (connecting cilium are required to form the outer segment), polydactyly (cilia 
dependent Shh is involved in limb bud development), situs inversus (defects in cilia in the 
embryonic node), anosmia (defective olfactory cilia) and infertility (due to sperm flagella 
defects)135. It seems likely but not proven that the cystic defects in these pleotropic disorders 
are due to mislocalization/function of the PC-complex and FPC.
Role of the PC complex on cilia—Although there is good evidence that the PC 
complex is found on cilia and that cilia are associated with cyst development, the precise 
role of the PC complex on the cilium is more controversial. It is known that cilia can act as a 
flow sensor and that changes in flow or mechanical movement of the cilium induces an 
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influx of Ca2+ 147. Cells null for Pkd1, or blocked for PC2, have been shown to lose the 
Ca2+ influx in response to flow, suggesting that the PC complex is a ciliary flow 
receptor148, 149. Additional evidence suggests that PC2 may be involved in flow detection in 
the cilia, but in combination with a different TRP channel, TRPV4150. In the embryonic 
node, PC2 also plays a role in flow detection, but this time in combination with the PC1-like 
protein, PC1L1, with the PC2/ PC1L1 complex sensing nodal flow151-153 (Figure 3). This is 
consistent with Pkd2 but not Pkd1 mice having situs inversus154, 155. A non-dimerizing PC2 
mutant (PC2-4M) that cannot bind to PC1 but still has the ability to function as an ER-
located Ca2+ release channel and can partially rescue LR asymmetry in a pkd2 zebrafish 
model, may be associated with this role for PC214. However, inactivation of Trpv4 or Pkd1l1 
is not associated with cyst development, questioning the link between ciliary flow sensing 
and PKD.
Polycystins and ciliary calcium regulation—Recently, the concept that the PC1/2 
complex regulates the level of ciliary Ca2+ has also been thrown into doubt with the PC1L1/
PC1L2 complex implicated in that task156, 157 (Figure 3). Furthermore, the authors argue 
that a change in Ca2+ concentration in the cilium is insufficient to trigger a global 
cytoplasmic Ca2+ response. Nevertheless, given the likely involvement of the PC1/2 
complex in Ca2+ regulation and the links to cilia and PKD, this issue is incompletely 
resolved. It is possible that a stimulus other than flow (ligand/s) may be important to activate 
the PC complex. In addition, localized differences in Ca2+ concentration, such as around the 
ciliary base and/or additional signal amplification, e.g. through cAMP158, 159, should be 
considered as ways that a cilia cue could be perpetuated to the cell.
Cilia, polycystins and other signalling—PC1 and PC2 are secreted at high levels in 
exosomes and may be involved in mediating distal nephron signalling possibly by 
interacting with cilia160-162. Other signalling pathways likely involving cilia have also been 
implicated in PKD. Changes in oriented cell division (OCD) in elongating tubules were 
found in the PCK rat model of ARPKD163. Planar cell polarity (PCP) which is linked to 
functional cilia, regulates this process, suggesting a role for PCP in controling tubule 
dilatation164. PC1 deficient cells also appear to lack directional movement in relation to a 
stimulus possibly reflecting a PCP defect165. However, evidence of an essential role of 
abnormal OCD in cyst formation in ADPKD is conflicting166, 167. A role for PCP more 
generally in ciliopathies is also questioned by findings of normal classical PCP processes, 
such as orientation of motile cilia and asymmetric expression of Vangl1 during inner ear 
development, in an MKS animal model, bpck168. An alternative explanation involves the 
related process, convergent-extension, which controls cell movements during tubular 
elongation 169; which is dysregulated in Pkd1 mice170.
Recently, a role for Shh signaling in PKD was been suggested with mutation to an IFT 
component IFT139 that results in abnormal Shh signaling causing cyst development, as well 
as other ciliopathy phenotypes171. Interestingly, inhibition of Shh in kidney organ culture 
resulted in reduced cystogenesis in a Pkd1 model172. Mutations in the Kruppel-like zinc 
finger transcription factor, Gli-similar 3 (Glis3), result in neonatal diabetes, hypothyroidism 
and PKD in humans and mice173, 174. GLIS3 has been localised to primary cilia and 
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interacts with the transcriptional co-regulator protein, WWtr1/Taz, and Glis3 mutant kidneys 
have lower Pkd1 mRNA levels, indicating that GLIS3 may regulate Pkd1 transcription174.
Cell cycle regulation and centrosome duplication—PC1 and PC2 appear to regulate 
the transcription of the cyclin-dependent kinase inhibitor p21, via JAK2-STAT3 signalling93. 
This could explain in part, the increased proliferation rate observed in non-cystic tubules and 
the exaggerated proliferative response following renal injury128, 175. In addition, PC2 may 
further regulate the nuclear translocation of p21 through its cytoplasmic retention by binding 
to the Id2 protein176. PC1 and PC2 deficient cells also have an abnormal increase in 
centrosome number, which could lead to abnormalities in proliferation control or result in 
apoptosis177. It is not clear whether this represents a primary effect of centrosomal 
duplication or is secondary to abnormal cell cycle regulation.
Cilium signalling promotes cyst growth—A surprising study in conditional knockout 
models of Pkd1 and Pkd2, and genes essential for cilia formation, Ift88 and Ift20, showed 
that elimination of cilia as well as loss of the PC resulted in much milder disease than loss of 
the PC alone178. This has been interpreted as the presence of a growth-promoting stimulus 
from cilia that is normally suppressed by the PC complex. However, while it is know that 
ciliary signalling can have a growth stimulating effect through regulation of the cell/
centrosome cycles, direct linkage with the PC complex seems less certain.
Non-cilia functions of polycystins
Regulation of stretch-activated channels
In mesenteric arteries, a mechanism involving PC2 in suppressing stretch activated currents 
(SAC) has been proposed which does not involve its channel activity179. The role of PC1 is 
to titrate the amounts of PC2. PC1 and PC2 also regulate the opening of stretch-activated K 
(2P) channels in kidney cells conferring protection against apoptosis induced by mechanical 
stress: a mechanism that may be operational during cyst growth180.
Basolateral localisation function and polarity
The proposed basolateral location of PC1 fits well with evidence that PC1 regulates or 
mediates cell-cell or cell-matrix adhesion82. Results from a recent study supports this idea 
showing a remarkable suppression of the Pkd1 cystic phenotype when combined with 
deletion of Ś1 integrin181.
Abnormalities in apicobasal polarity are an inconsistent finding in PC1 and PC2 deficient 
cells but abnormalities in cell-cell junction formation are commonly found182, 183. 
Alterations in the basolateral trafficking of E-cadherin have been linked to misregulation of 
components of the exocyst complex (sec6, sec8), which are important in the establishment of 
the basolateral domain of epithelial cells184. PC2 has also been shown to bind to Sec10, 
although this has been linked to cilia rather than basolateral trafficking of PC2185. It is 
conceivable that the role of PC1 in mediating cell-cell adhesion, through trans-homophilic 
interactions, and to recruit E-cadherin through cis-heterophilic interactions, could regulate 
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this process81. Changes in intercellular adhesion are paralleled by changes in cell-matrix 
adhesion especially to collagen I186.
Functions of other polycystins
We have discussed the role of PC1L1 with PC2 in the embryonic node and PC1L1 and 
PC2L1 in regulating ciliary calcium, but other members also have diverse functions (Figure 
3). PC1REJ has been shown to mediate the sperm acrosome reaction187 and PC1L3 to be the 
sour taste (H+) detector188. The role of PC1L2 is less clear but up-regulation in mice results 
in chronic neuromuscular impairment189 while PC2L2 has been implicated in 
spermatogenesis190. In addition to what is presently known, other combinations between 
PC1 and PC2 paralogs likely mediate other cilia related and unrelated functions.
Polycystin complex formation, maturation and trafficking
The localisation of both PC1 and PC2 to different subcellular compartments (cilia, PM, ER 
and exosomes) has led to uncertainty whether the trafficking of both proteins is co-
dependent, the nature of the targeting, export or retrieval motifs, and the functional site/s of 
action to prevent PKD.
Ciliary and PM complexes
PC2 is most abundantly found in the ER, consistent with the normal appearance of only an 
immature (EndoH sensitive) glycoform12. PC1 generates mature (EndoH resistant; NTR, 
CTR) and immature (EndoH sensitive; NTS, CTS) glycoforms11 with NTR found on the 
PM, cilia and exported via the multivesicular pathway in exosomes36, 68, 74, 75, 161 (Figure 
4). In contrast, NTS likely remains in the ER along with any unGPS-cleaved PC1. PC1 
binding to PC2 is absolutely dependent on PC2 oligomerisation via its C-terminus 14 and 
PC1 maturation and localization requires PC2 in a dose-dependent manner68, 74. PC1 
cleavage at the GPS/GAIN domain is a requirement for PC1 maturation and the generation 
of PC1 NTR68, 74. A PC1 NTP unlinked to the PC1 CTP has been reported at the plasma 
membrane75 but transgenic expression an NTP-like protein (F3043X) could not rescue the 
phenotype of GPS cleavage–deficient Pkd1v/v (T3041V) mice75. It is unclear if the isolated 
PC1-CTP is functional but one study has shown that expression of the transgene is stabilised 
by PC2 binding109.
Both PC1 and PC2 are present in the cis-Golgi, but at this point it is uncertain whether they 
continue to be co-transported through the Golgi for maturation and export to cilia. It has 
been suggested that they become uncoupled at the cis-Golgi and undergo independent 
trafficking at this point and recouple in a post-Golgi compartment106. However, recent 
evidence of a cilia localized EndoH-resistant (mature) form of PC2 suggests that they may 
traffic together to that organelle74. Transport of PC2 and PC1 to PM membranes may be 
similarly co-dependent73, 74, 191. The low level of surface labelling of PC2 compared to PC1, 
questions whether PM PC1 may interact with ER PC2 in membrane subdomains14, 68, 
possibly in cooperation with IP3 receptors15.
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In conclusion
In 20 years, extensive information about the mechanism of disease in ADPKD, the structure 
of the polycystins and where they are localized has been determined. The challenges now are 
to determine exactly what the PC1/2 complex does in the cilium, if PC1/2 localization 
elsewhere is significant to pathogenesis and whether PC1/2 levels are rate-limiting for the 
onset of PKD with other cystoproteins. Answers to these questions would stimulate new 
therapeutic options to target cyst initiation in ADPKD and other cystic diseases.
Acknowledgements
Work in the author’ s laboratories was supported by grants from the Wellcome Trust, Medical Research Council, 
Research Councils UK, Kidney Research UK, PKD Foundation, European Union (EU-FP7/2007-2013, grant 
agreement no. 317246, TranCYST) and NIH/NIDDK (DK058816 and DK090728). We thank past and present 
members of the Ong and Harris laboratories for significant contributions to this work and for many stimulating 
discussions.
References
1. Ong AC, Devuyst O, Knebelmann B, et al. Autosomal dominant polycystic kidney disease: the 
changing face of clinical management. Lancet. 2015 in press. 
2. Chang MY, Ong AC. New treatments for autosomal dominant polycystic kidney disease. Br J Clin 
Pharmacol. 2013; 76:524–535. [PubMed: 23594398] 
3. Paul BM, Consugar MB, Ryan Lee M, et al. Evidence of a third ADPKD locus is not supported by 
re-analysis of designated PKD3 families. Kidney Int. 2014; 85:383–392. [PubMed: 23760289] 
4. Cornec-Le Gall E, Audrezet MP, Chen JM, et al. Type of PKD1 mutation influences renal outcome 
in ADPKD. J Am Soc Nephrol. 2013; 24:1006–1013. [PubMed: 23431072] 
5. Ong AC, Harris PC. Molecular pathogenesis of ADPKD: The polycystin complex gets complex. 
Kidney Int. 2005; 67:1234–1247. [PubMed: 15780076] 
6. Ong AC, Ward CJ, Butler RJ, et al. Coordinate expression of the autosomal dominant polycystic 
kidney disease proteins, polycystin-2 and polycystin-1, in normal and cystic tissue. Am J Pathol. 
1999; 154:1721–1729. [PubMed: 10362797] 
7. Foggensteiner L, Bevan AP, Thomas R, et al. Cellular and subcellular distribution of polycystin-2, 
the protein product of the PKD2 gene. J Am Soc Nephrol. 2000; 11:814–827. [PubMed: 10770959] 
8. Guillaume R, Trudel M. Distinct and common developmental expression patterns of the murine 
Pkd2 and Pkd1 genes. Mech Dev. 2000; 93:179–183. [PubMed: 10781953] 
9. Qian F, Germino FJ, Cai Y, et al. PKD1 interacts with PKD2 through a probable coiled-coil domain. 
Nature genetics. 1997; 16:179–183. [PubMed: 9171830] 
10. Tsiokas L, Kim E, Arnould T, et al. Homo- and heterodimeric interactions between the gene 
products of PKD1 and PKD2. Proc Natl Acad Sci U S A. 1997; 94:6965–6970. [PubMed: 
9192675] 
11. Newby LJ, Streets AJ, Zhao Y, et al. Identification, characterization, and localization of a novel 
kidney polycystin-1-polycystin-2 complex. J Biol Chem. 2002; 277:20763–20773. [PubMed: 
11901144] 
12. Cai Y, Maeda Y, Cedzich A, et al. Identification and characterization of polycystin-2, the PKD2 
gene product. J Biol Chem. 1999; 274:28557–28565. [PubMed: 10497221] 
13. Koulen P, Cai Y, Geng L, et al. Polycystin-2 is an intracellular calcium release channel. Nat Cell 
Biol. 2002; 4:191–197. [PubMed: 11854751] 
14. Giamarchi A, Feng S, Rodat-Despoix L, et al. A polycystin-2 (TRPP2) dimerization domain 
essential for the function of heteromeric polycystin complexes. EMBO J. 2010; 29:1176–1191. 
[PubMed: 20168298] 
15. Mekahli D, Sammels E, Luyten T, et al. Polycystin-1 and polycystin-2 are both required to amplify 
inositol-trisphosphate-induced Ca(2+) release. Cell calcium. 2012
Ong and Harris Page 12
Kidney Int. Author manuscript; available in PMC 2016 April 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
16. Lu W, Peissel B, Babakhanlou H, et al. Perinatal lethality with kidney and pancreas defects in mice 
with a targetted Pkd1 mutation. Nat Genet. 1997; 17:179–181. [PubMed: 9326937] 
17. Wu G, Markowitz GS, Li L, et al. Cardiac defects and renal failure in mice with targeted mutations 
in Pkd2. Nat Genet. 2000; 24:75–78. [PubMed: 10615132] 
18. Ong AC, Harris PC. Molecular basis of renal cyst formation--one hit or two? Lancet. 1997; 
349:1039–1040. [PubMed: 9107237] 
19. Qian F, Watnick TJ, Onuchic LF, et al. The molecular basis of focal cyst formation in human 
autosomal dominant polycystic kidney disease type I. Cell. 1996; 87:979–987. [PubMed: 
8978603] 
20. Watnick TJ, Torres VE, Gandolph MA, et al. Somatic mutation in individual liver cysts supports a 
two-hit model of cystogenesis in autosomal dominant polycystic kidney disease. Mol Cell. 1998; 
2:247–251. [PubMed: 9734362] 
21. Pei Y, Watnick T, He N, et al. Somatic PKD2 mutations in individual kidney and liver cysts support 
a “two-hit” model of cystogenesis in type 2 autosomal dominant polycystic kidney disease. J Am 
Soc Nephrol. 1999; 10:1524–1529. [PubMed: 10405208] 
22. Wu G, D’ Agati V, Cai Y, et al. Somatic inactivation of Pkd2 results in polycystic kidney disease. 
Cell. 1998; 93:177–188. [PubMed: 9568711] 
23. Piontek K, Menezes LF, Garcia-Gonzalez MA, et al. A critical developmental switch defines the 
kinetics of kidney cyst formation after loss of Pkd1. Nat Med. 2007; 13:1490–1495. [PubMed: 
17965720] 
24. Lantinga-van Leeuwen IS, Leonhard WN, van der Wal A, et al. Kidney-specific inactivation of the 
Pkd1 gene induces rapid cyst formation in developing kidneys and a slow onset of disease in adult 
mice. Hum Mol Genet. 2007; 16:3188–3196. [PubMed: 17932118] 
25. Harris PC, Bae KT, Rossetti S, et al. Cyst number but not the rate of cystic growth is associated 
with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2006; 
17:3013–3019. [PubMed: 17035604] 
26. Lantinga-van Leeuwen IS, Dauwerse JG, Baelde HJ, et al. Lowering of Pkd1 expression is 
sufficient to cause polycystic kidney disease. Hum Mol Genet. 2004; 13:3069–3077. [PubMed: 
15496422] 
27. Jiang ST, Chiou YY, Wang E, et al. Defining a link with autosomal-dominant polycystic kidney 
disease in mice with congenitally low expression of Pkd1. Am J Pathol. 2006; 168:205–220. 
[PubMed: 16400024] 
28. Nishio S, Hatano M, Nagata M, et al. Pkd1 regulates immortalized proliferation of renal tubular 
epithelial cells through p53 induction and JNK activation. J Clin Invest. 2005; 115:910–918. 
[PubMed: 15761494] 
29. Watnick T, He N, Wang K, et al. Mutations of PKD1 in ADPKD2 cysts suggest a pathogenic effect 
of trans-heterozygous mutations. Nat Genet. 2000; 25:143–144. [PubMed: 10835625] 
30. Koptides M, Mean R, Demetriou K, et al. Genetic evidence for a trans-heterozygous model for 
cystogenesis in autosomal dominant polycystic kidney disease. Hum Mol Genet. 2000; 9:447–452. 
[PubMed: 10655555] 
31. Gogusev J, Murakami I, Doussau M, et al. Molecular cytogenetic aberrations in autosomal 
dominant polycystic kidney disease tissue. J Am Soc Nephrol. 2003; 14:359–366. [PubMed: 
12538736] 
32. Rossetti S, Kubly VJ, Consugar MB, et al. Incompletely penetrant PKD1 alleles suggest a role for 
gene dosage in cyst initiation in polycystic kidney disease. Kidney Int. 2009; 75:848–855. 
[PubMed: 19165178] 
33. Vujic M, Heyer CM, Ars E, et al. Incompletely penetrant PKD1 alleles mimic the renal 
manifestations of ARPKD. J Am Soc Nephrol. 2010; 21:1097–1102. [PubMed: 20558538] 
34. Bergmann C, von Bothmer J, Ortiz Bruchle N, et al. Mutations in multiple PKD genes may explain 
early and severe polycystic kidney disease. Journal of the American Society of Nephrology: JASN. 
2011; 22:2047–2056. [PubMed: 22034641] 
35. Losekoot M, Ruivenkamp CA, Tholens AP, et al. Neonatal onset autosomal dominant polycystic 
kidney disease (ADPKD) in a patient homozygous for a PKD2 missense mutation due to 
uniparental disomy. Journal of medical genetics. 2012; 49:37–40. [PubMed: 22114106] 
Ong and Harris Page 13
Kidney Int. Author manuscript; available in PMC 2016 April 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
36. Hopp K, Ward CJ, Hommerding CJ, et al. Functional polycystin-1 dosage governs autosomal 
dominant polycystic kidney disease severity. The Journal of clinical investigation. 2012; 
122:4257–4273. [PubMed: 23064367] 
37. Raj A, Rifkin SA, Andersen E, et al. Variability in gene expression underlies incomplete 
penetrance. Nature. 2010; 463:913–918. [PubMed: 20164922] 
38. Ong AC, Harris PC, Davies DR, et al. Polycystin-1 expression in PKD1, early-onset PKD1, and 
TSC2/PKD1 cystic tissue. Kidney Int. 1999; 56:1324–1333. [PubMed: 10504485] 
39. Bastos AP, Piontek K, Silva AM, et al. Pkd1 haploinsufficiency increases renal damage and 
induces microcyst formation following ischemia/reperfusion. Journal of the American Society of 
Nephrology: JASN. 2009; 20:2389–2402. [PubMed: 19833899] 
40. Happe H, Leonhard WN, van der Wal A, et al. Toxic tubular injury in kidneys from Pkd1-deletion 
mice accelerates cystogenesis accompanied by dysregulated planar cell polarity and canonical Wnt 
signaling pathways. Human molecular genetics. 2009; 18:2532–2542. [PubMed: 19401297] 
41. Fedeles SV, Tian X, Gallagher AR, et al. A genetic interaction network of five genes for human 
polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst 
formation. Nature genetics. 2011; 43:639–647. [PubMed: 21685914] 
42. Raphael KL, Strait KA, Stricklett PK, et al. Inactivation of Pkd1 in principal cells causes a more 
severe cystic kidney disease than in intercalated cells. Kidney Int. 2009; 75:626–633. [PubMed: 
19145237] 
43. Leonhard WN, Zandbergen M, Veraar K, et al. Scattered Deletion of PKD1 in Kidneys Causes a 
Cystic Snowball Effect and Recapitulates Polycystic Kidney Disease. J Am Soc Nephrol. 2014
44. Faguer S, Chassaing N, Bandin F, et al. The HNF1B score is a simple tool to select patients for 
HNF1B gene analysis. Kidney Int. 2014; 86:1007–1015. [PubMed: 24897035] 
45. Gresh L, Fischer E, Reimann A, et al. A transcriptional network in polycystic kidney disease. 
EMBO J. 2004; 23:1657–1668. [PubMed: 15029248] 
46. Patel V, Williams D, Hajarnis S, et al. miR-17~92 miRNA cluster promotes kidney cyst growth in 
polycystic kidney disease. Proc Natl Acad Sci U S A. 2013; 110:10765–10770. [PubMed: 
23759744] 
47. Wang E, Hsieh-Li HM, Chiou YY, et al. Progressive renal distortion by multiple cysts in transgenic 
mice expressing artificial microRNAs against Pkd1. J Pathol. 2010; 222:238–248. [PubMed: 
20814903] 
48. Tran U, Zakin L, Schweickert A, et al. The RNA-binding protein bicaudal C regulates polycystin 2 
in the kidney by antagonizing miR-17 activity. Development. 2010; 137:1107–1116. [PubMed: 
20215348] 
49. Kim K, Drummond I, Ibraghimov-Beskrovnaya O, et al. Polycystin 1 is required for the structural 
integrity of blood vessels. Proc Natl Acad Sci U S A. 2000; 97:1731–1736. [PubMed: 10677526] 
50. Gevers TJ, Drenth JP. Diagnosis and management of polycystic liver disease. Nature reviews 
Gastroenterology & hepatology. 2013; 10:101–108. [PubMed: 23296249] 
51. Rossetti S, Chauveau D, Kubly V, et al. Association of mutation position in polycystic kidney 
disease 1 (PKD1) gene and development of a vascular phenotype. Lancet. 2003; 361:2196–2201. 
[PubMed: 12842373] 
52. Ring T, Spiegelhalter D. Risk of intracranial aneurysm bleeding in autosomal-dominant polycystic 
kidney disease. Kidney Int. 2007; 72:1400–1402. [PubMed: 17882153] 
53. Ong AC. Screening for intracranial aneurysms in ADPKD. Bmj. 2009; 339:b3763. [PubMed: 
19770180] 
54. Thong KM, Ong AC. Sudden death due to subarachnoid haemorrhage in an infant with autosomal 
dominant polycystic kidney disease. Nephrol Dial Transplant. 2014; 29(Suppl 4):iv121–iv123. 
[PubMed: 25165178] 
55. Kurbegovic A, Cote O, Couillard M, et al. Pkd1 transgenic mice: adult model of polycystic kidney 
disease with extrarenal and renal phenotypes. Hum Mol Genet. 2010; 19:1174–1189. [PubMed: 
20053665] 
56. Qian Q, Hunter LW, Li M, et al. Pkd2 haploinsufficiency alters intracellular calcium regulation in 
vascular smooth muscle cells. Hum Mol Genet. 2003; 12:1875–1880. [PubMed: 12874107] 
Ong and Harris Page 14
Kidney Int. Author manuscript; available in PMC 2016 April 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
57. Hassane S, Claij N, Lantinga-van Leeuwen IS, et al. Pathogenic Sequence for Dissecting 
Aneurysm Formation in a Hypomorphic Polycystic Kidney Disease 1 Mouse Model. Arterioscler 
Thromb Vasc Biol. 2007
58. Hassane S, Claij N, Jodar M, et al. Pkd1-inactivation in vascular smooth muscle cells and 
adaptation to hypertension. Lab Invest. 2011; 91:24–32. [PubMed: 20856231] 
59. Brookes ZL, Ruff L, Upadhyay VS, et al. Pkd2 mesenteric vessels exhibit a primary defect in 
endothelium-dependent vasodilatation restored by rosiglitazone. American journal of physiology 
Heart and circulatory physiology. 2013; 304:H33–41. [PubMed: 23103499] 
60. Brook-Carter PT, Peral B, Ward CJ, et al. Deletion of the TSC2 and PKD1 genes associated with 
severe infantile polycystic kidney disease--a contiguous gene syndrome. Nat Genet. 1994; 8:328–
332. [PubMed: 7894481] 
61. Sampson JR, Maheshwar MM, Aspinwall R, et al. Renal cystic disease in tuberous sclerosis: role 
of the polycystic kidney disease 1 gene. Am J Hum Genet. 1997; 61:843–851. [PubMed: 9382094] 
62. Hartman TR, Liu D, Zilfou JT, et al. The Tuberous Sclerosis Proteins Regulate Formation of the 
Primary Cilium via a Rapamycin-Insensitive and Polycystin 1-Independent Pathway. Hum Mol 
Genet. 2008
63. Bonnet CS, Aldred M, von Ruhland C, et al. Defects in cell polarity underlie TSC and ADPKD-
associated cystogenesis. Hum Mol Genet. 2009; 18:2166–2176. [PubMed: 19321600] 
64. Kleymenova E, Ibraghimov-Beskrovnaya O, Kugoh H, et al. Tuberin-dependent membrane 
localization of polycystin-1: a functional link between polycystic kidney disease and the TSC2 
tumor suppressor gene. Mol Cell. 2001; 7:823–832. [PubMed: 11336705] 
65. Kim I, Fu Y, Hui K, et al. Fibrocystin/polyductin modulates renal tubular formation by regulating 
polycystin-2 expression and function. J Am Soc Nephrol. 2008; 19:455–468. [PubMed: 18235088] 
66. Pei Y, Paterson AD, Wang KR, et al. Bilineal disease and trans-heterozygotes in autosomal 
dominant polycystic kidney disease. Am J Hum Genet. 2001; 68:355–363. [PubMed: 11156533] 
67. Pei Y, Lan Z, Wang K, et al. A missense mutation in PKD1 attenuates the severity of renal disease. 
Kidney international. 2012; 81:412–417. [PubMed: 22031115] 
68. Gainullin VG, Hopp K, Ward CJ, et al. Polycystin-1 maturation requires polycystin-2 in a dose-
dependent manner. J Clin Invest. 2015
69. Hofherr A, Wagner C, Fedeles S, et al. N-glycosylation determines the abundance of the transient 
receptor potential channel TRPP2. J Biol Chem. 2014; 289:14854–14867. [PubMed: 24719335] 
70. Li A, Davila S, Furu L, et al. Mutations in PRKCSH Cause Isolated Autosomal Dominant 
Polycystic Liver Disease. Am J Hum Genet. 2003; 72:691–703. [PubMed: 12529853] 
71. Arac D, Boucard AA, Bolliger MF, et al. A novel evolutionarily conserved domain of cell-adhesion 
GPCRs mediates autoproteolysis. The EMBO journal. 2012; 31:1364–1378. [PubMed: 22333914] 
72. Yu S, Hackmann K, Gao J, et al. Essential role of cleavage of Polycystin-1 at G protein-coupled 
receptor proteolytic site for kidney tubular structure. Proc Natl Acad Sci U S A. 2007; 104:18688–
18693. [PubMed: 18003909] 
73. Chapin HC, Rajendran V, Caplan MJ. Polycystin-1 surface localization is stimulated by 
polycystin-2 and cleavage at the G protein-coupled receptor proteolytic site. Molecular biology of 
the cell. 2010; 21:4338–4348. [PubMed: 20980620] 
74. Kim H, Xu H, Yao Q, et al. Ciliary membrane proteins traffic through the Golgi via a Rabep1/
GGA1/Arl3-dependent mechanism. Nat Commun. 2014; 5:5482. [PubMed: 25405894] 
75. Kurbegovic A, Kim H, Xu H, et al. Novel functional complexity of polycystin-1 by GPS cleavage 
in vivo: role in polycystic kidney disease. Mol Cell Biol. 2014; 34:3341–3353. [PubMed: 
24958103] 
76. Bycroft M, Bateman A, Clarke J, et al. The structure of a PKD domain from polycystin-1: 
implications for polycystic kidney disease. EMBO J. 1999; 18:297–305. [PubMed: 9889186] 
77. Jing H, Takagi J, Liu JH, et al. Archaeal surface layer proteins contain beta propeller, PKD, and 
beta helix domains and are related to metazoan cell surface proteins. Structure. 2002; 10:1453–
1464. [PubMed: 12377130] 
78. Qian F, Wei W, Germino G, et al. The nanomechanics of polycystin-1 extracellular region. J Biol 
Chem. 2005; 280:40723–40730. [PubMed: 16219758] 
Ong and Harris Page 15
Kidney Int. Author manuscript; available in PMC 2016 April 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
79. Forman JR, Qamar S, Paci E, et al. The remarkable mechanical strength of polycystin-1 supports a 
direct role in mechanotransduction. J Mol Biol. 2005; 349:861–871. [PubMed: 15894330] 
80. Forman JR, Yew ZT, Qamar S, et al. Non-native interactions are critical for mechanical strength in 
PKD domains. Structure. 2009; 17:1582–1590. [PubMed: 20004162] 
81. Streets AJ, Wagner BE, Harris PC, et al. Homophilic and heterophilic polycystin 1 interactions 
regulate E-cadherin recruitment and junction assembly in MDCK cells. J Cell Sci. 2009; 
122:1410–1417. [PubMed: 19351715] 
82. Streets AJ, Newby LJ, O’ Hare MJ, et al. Functional analysis of PKD1 transgenic lines reveals a 
direct role for polycystin-1 in mediating cell-cell adhesion. J Am Soc Nephrol. 2003; 14:1804–
1815. [PubMed: 12819240] 
83. Ibraghimov-Beskrovnaya O, Bukanov NO, Donohue LC, et al. Strong homophilic interactions of 
the Ig-like domains of polycystin-1, the protein product of an autosomal dominant polycystic 
kidney disease gene, PKD1. Hum Mol Genet. 2000; 9:1641–1649. [PubMed: 10861291] 
84. Bateman A, Sandford R. The PLAT domain: a new piece in the PKD1 puzzle. Curr Biol. 1999; 
9:R588–590. [PubMed: 10469604] 
85. Ponting CP, Hofmann K, Bork P. A latrophilin/CL-1-like GPS domain in polycystin-1. Curr Biol. 
1999; 9:R585–588. [PubMed: 10469603] 
86. Recacha R, Boulet A, Jollivet F, et al. Structural basis for recruitment of Rab6-interacting protein 1 
to Golgi via a RUN domain. Structure. 2009; 17:21–30. [PubMed: 19141279] 
87. Eek P, Järving R, Järving I, et al. Structure of a calcium-dependent 11R-lipoxygenase suggests a 
mechanism for Ca2+ regulation. J Biol Chem. 2012; 287:22377–22386. [PubMed: 22573333] 
88. Hu J, Barr MM. ATP-2 interacts with the PLAT domain of LOV-1 and is involved in 
Caenorhabditis elegans polycystin signaling. Mol Biol Cell. 2005; 16:458–469. [PubMed: 
15563610] 
89. Parnell SC, Puri S, Wallace DP, et al. Protein phosphatase-1alpha interacts with and 
dephosphorylates polycystin-1. PloS one. 2012; 7:e36798. [PubMed: 22675472] 
90. Streets AJ, Wessely O, Peters DJ, et al. Hyperphosphorylation of polycystin-2 at a critical residue 
in disease reveals an essential role for polycystin-1-regulated dephosphorylation. Human 
molecular genetics. 2013; 22:1924–1939. [PubMed: 23390129] 
91. Shillingford JM, Murcia NS, Larson CH, et al. The mTOR pathway is regulated by polycystin-1, 
and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S 
A. 2006; 103:5466–5471. [PubMed: 16567633] 
92. Lal M, Song X, Pluznick JL, et al. Polycystin-1 C-terminal tail associates with beta-catenin and 
inhibits canonical Wnt signaling. Hum Mol Genet. 2008; 17:3105–3117. [PubMed: 18632682] 
93. Bhunia AK, Piontek K, Boletta A, et al. PKD1 Induces p21(waf1) and Regulation of the Cell Cycle 
via Direct Activation of the JAK-STAT Signaling Pathway in a Process Requiring PKD2. Cell. 
2002; 109:157–168. [PubMed: 12007403] 
94. Gonzalez-Perret S, Kim K, Ibarra C, et al. Polycystin-2, the protein mutated in autosomal dominant 
polycystic kidney disease (ADPKD), is a Ca2+-permeable nonselective cation channel. Proc Natl 
Acad Sci U S A. 2001; 98:1182–1187. [PubMed: 11252306] 
95. Ma R, Li WP, Rundle D, et al. PKD2 functions as an epidermal growth factor-activated plasma 
membrane channel. Mol Cell Biol. 2005; 25:8285–8298. [PubMed: 16135816] 
96. Montell C, Birnbaumer L, Flockerzi V, et al. A unified nomenclature for the superfamily of TRP 
cation channels. Mol Cell. 2002; 9:229–231. [PubMed: 11864597] 
97. Torres VE, Harris PC. Strategies targeting cAMP signaling in the treatment of polycystic kidney 
disease. J Am Soc Nephrol. 2014; 25:18–32. [PubMed: 24335972] 
98. Yu Y, Ulbrich MH, Li MH, et al. Structural and molecular basis of the assembly of the TRPP2/
PKD1 complex. Proc Natl Acad Sci U S A. 2009; 106:11558–11563. [PubMed: 19556541] 
99. Zhang P, Luo Y, Chasan B, et al. The multimeric structure of polycystin-2 (TRPP2): structural-
functional correlates of homo- and hetero-multimers with TRPC1. Hum Mol Genet. 2009; 
18:1238–1251. [PubMed: 19193631] 
100. Feng S, Okenka GM, Bai CX, et al. Identification and Functional Characterization of an N-
terminal Oligomerization Domain for Polycystin-2. J Biol Chem. 2008; 283:28471–28479. 
[PubMed: 18701462] 
Ong and Harris Page 16
Kidney Int. Author manuscript; available in PMC 2016 April 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
101. Feng S, Rodat-Despoix L, Delmas P, et al. A Single Amino Acid Residue Constitutes the Third 
Dimerization Domain Essential for the Assembly and Function of the Tetrameric Polycystin-2 
(TRPP2) Channel. The Journal of biological chemistry. 2011; 286:18994–19000. [PubMed: 
21474446] 
102. Petri ET, Celic A, Kennedy SD, et al. Structure of the EF-hand domain of polycystin-2 suggests a 
mechanism for Ca2+-dependent regulation of polycystin-2 channel activity. Proc Natl Acad Sci 
U S A. 2010; 107:9176–9181. [PubMed: 20439752] 
103. Schumann F, Hoffmeister H, Bader R, et al. Ca2+-dependent conformational changes in a C-
terminal cytosolic domain of polycystin-2. J Biol Chem. 2009; 284:24372–24383. [PubMed: 
19546223] 
104. Cantero Mdel R, Cantiello HF. Calcium Transport and Local Pool Regulate Polycystin-2 (TRPP2) 
Function in Human Syncytiotrophoblast. Biophysical journal. 2013; 105:365–375. [PubMed: 
23870258] 
105. Geng L, Okuhara D, Yu Z, et al. Polycystin-2 traffics to cilia independently of polycystin-1 by 
using an N-terminal RVxP motif. J Cell Sci. 2006; 119:1383–1395. [PubMed: 16537653] 
106. Hoffmeister H, Babinger K, Gurster S, et al. Polycystin-2 takes different routes to the somatic and 
ciliary plasma membrane. J Cell Biol. 2011; 192:631–645. [PubMed: 21321097] 
107. Yoshiba S, Shiratori H, Kuo IY, et al. Cilia at the node of mouse embryos sense fluid flow for left-
right determination via Pkd2. Science. 2012; 338:226–231. [PubMed: 22983710] 
108. Ward HH, Brown-Glaberman U, Wang J, et al. A conserved signal and GTPase complex are 
required for the ciliary transport of polycystin-1. Mol Biol Cell. 2011; 22:3289–3305. [PubMed: 
21775626] 
109. Cai Y, Fedeles SV, Dong K, et al. Altered trafficking and stability of polycystins underlie 
polycystic kidney disease. J Clin Invest. 2014; 124:5129–5144. [PubMed: 25365220] 
110. Streets AJ, Moon DJ, Kane ME, et al. Identification of an N-terminal glycogen synthase kinase 3 
phosphorylation site which regulates the functional localization of polycystin-2 in vivo and in 
vitro. Hum Mol Genet. 2006; 15:1465–1473. [PubMed: 16551655] 
111. Miyakawa A, Ibarra C, Malmersjo S, et al. Intracellular calcium release modulates polycystin-2 
trafficking. BMC Nephrol. 2013; 14:34. [PubMed: 23398808] 
112. Cai Y, Anyatonwu G, Okuhara D, et al. Calcium dependence of polycystin-2 channel activity is 
modulated by phosphorylation at Ser812. J Biol Chem. 2004; 279:19987–19995. [PubMed: 
14742446] 
113. Streets AJ, Needham AJ, Gill SK, et al. Protein kinase D-mediated phosphorylation of 
polycystin-2 (TRPP2) is essential for its effects on cell growth and calcium channel activity. 
Molecular biology of the cell. 2010; 21:3853–3865. [PubMed: 20881056] 
114. Kottgen M, Benzing T, Simmen T, et al. Trafficking of TRPP2 by PACS proteins represents a 
novel mechanism of ion channel regulation. EMBO J. 2005; 24:705–716. [PubMed: 15692563] 
115. Boucher CA, Ward HH, Case RL, et al. Receptor protein tyrosine phosphatases are novel 
components of a polycystin complex. Biochimica et biophysica acta. 2011; 1812:1225–1238. 
[PubMed: 21126580] 
116. Otto EA, Trapp ML, Schultheiss UT, et al. NEK8 mutations affect ciliary and centrosomal 
localization and may cause nephronophthisis. J Am Soc Nephrol. 2008; 19:587–592. [PubMed: 
18199800] 
117. Liu S, Lu W, Obara T, et al. A defect in a novel Nek-family kinase causes cystic kidney disease in 
the mouse and in zebrafish. Development. 2002; 129:5839–5846. [PubMed: 12421721] 
118. McCooke JK, Appels R, Barrero RA, et al. A novel mutation causing nephronophthisis in the 
Lewis polycystic kidney rat localises to a conserved RCC1 domain in Nek8. BMC Genomics. 
2012; 13:393. [PubMed: 22899815] 
119. Sohara E, Luo Y, Zhang J, et al. Nek8 regulates the expression and localization of polycystin-1 
and polycystin-2. J Am Soc Nephrol. 2008; 19:469–476. [PubMed: 18235101] 
120. Hoff S, Halbritter J, Epting D, et al. ANKS6 is a central component of a nephronophthisis module 
linking NEK8 to INVS and NPHP3. Nature genetics. 2013
Ong and Harris Page 17
Kidney Int. Author manuscript; available in PMC 2016 April 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
121. Kim H, Jeong W, Ahn K, et al. Siah-1 interacts with the intracellular region of polycystin-1 and 
affects its stability via the ubiquitin-proteasome pathway. J Am Soc Nephrol. 2004; 15:2042–
2049. [PubMed: 15284290] 
122. Tian Y, Kolb R, Hong JH, et al. TAZ promotes PC2 degradation through a SCFbeta-Trcp E3 
ligase complex. Mol Cell Biol. 2007; 27:6383–6395. [PubMed: 17636028] 
123. Makita R, Uchijima Y, Nishiyama K, et al. Multiple renal cysts, urinary concentration defects, 
and pulmonary emphysematous changes in mice lacking TAZ. American journal of physiology 
Renal physiology. 2008; 294:F542–553. [PubMed: 18172001] 
124. Yim H, Sung CK, You J, et al. Nek1 and TAZ interact to maintain normal levels of polycystin 2. 
Journal of the American Society of Nephrology: JASN. 2011; 22:832–837. [PubMed: 21474562] 
125. Azzolin L, Panciera T, Soligo S, et al. YAP/TAZ incorporation in the beta-catenin destruction 
complex orchestrates the Wnt response. Cell. 2014; 158:157–170. [PubMed: 24976009] 
126. Liang G, Li Q, Tang Y, et al. Polycystin-2 is regulated by endoplasmic reticulum-associated 
degradation. Hum Mol Genet. 2008; 17:1109–1119. [PubMed: 18178578] 
127. Gao H, Wang Y, Wegierski T, et al. PRKCSH/80K-H, the protein mutated in polycystic liver 
disease, protects polycystin-2/TRPP2 against HERP-mediated degradation. Hum Mol Genet. 
2010; 19:16–24. [PubMed: 19801576] 
128. Prasad S, McDaid JP, Tam FW, et al. Pkd2 dosage influences cellular repair responses following 
ischemia-reperfusion injury. Am J Pathol. 2009; 175:1493–1503. [PubMed: 19729489] 
129. Zhao Y, Haylor JL, Ong AC. Polycystin-2 expression is increased following experimental 
ischaemic renal injury. Nephrol Dial Transplant. 2002; 17:2138–2144. [PubMed: 12454224] 
130. Merrick D, Chapin H, Baggs JE, et al. The gamma-secretase cleavage product of polycystin-1 
regulates TCF and CHOP-mediated transcriptional activation through a p300-dependent 
mechanism. Developmental cell. 2012; 22:197–210. [PubMed: 22178500] 
131. Low SH, Vasanth S, Larson CH, et al. Polycystin-1, STAT6, and P100 Function in a Pathway that 
Transduces Ciliary Mechanosensation and Is Activated in Polycystic Kidney Disease. Dev Cell. 
2006; 10:57–69. [PubMed: 16399078] 
132. Woodward OM, Li Y, Yu S, et al. Identification of a polycystin-1 cleavage product, P100, that 
regulates store operated Ca entry through interactions with STIM1. PloS one. 2010; 5:e12305. 
[PubMed: 20808796] 
133. Ong AC, Wheatley DN. Polycystic kidney disease--the ciliary connection. Lancet. 2003; 
361:774–776. [PubMed: 12620752] 
134. Sung CH, Leroux MR. The roles of evolutionarily conserved functional modules in cilia-related 
trafficking. Nat Cell Biol. 2013; 15:1387–1397. [PubMed: 24296415] 
135. Hildebrandt F, Benzing T, Katsanis N. Ciliopathies. The New England journal of medicine. 2011; 
364:1533–1543. [PubMed: 21506742] 
136. Barr MM, DeModena J, Braun D, et al. The Caenorhabditis elegans autosomal dominant 
polycystic kidney disease gene homologs lov-1 and pkd-2 act in the same pathway. Curr Biol. 
2001; 11:1341–1346. [PubMed: 11553327] 
137. Barr MM, Sternberg PW. A polycystic kidney-disease gene homologue required for male mating 
behaviour in C. elegans. Nature. 1999; 401:386–389. [PubMed: 10517638] 
138. Pazour GJ, Dickert BL, Vucica Y, et al. Chlamydomonas IFT88 and its mouse homologue, 
polycystic kidney disease gene tg737, are required for assembly of cilia and flagella. J Cell Biol. 
2000; 151:709–718. [PubMed: 11062270] 
139. Haycraft CJ, Swoboda P, Taulman PD, et al. The C. elegans homolog of the murine cystic kidney 
disease gene Tg737 functions in a ciliogenic pathway and is disrupted in osm-5 mutant worms. 
Development. 2001; 128:1493–1505. [PubMed: 11290289] 
140. Yoder BK, Hou X, Guay-Woodford LM. The polycystic kidney disease proteins, polycystin-1, 
polycystin-2, polaris, and cystin, are co-localized in renal cilia. J Am Soc Nephrol. 2002; 
13:2508–2516. [PubMed: 12239239] 
141. Pazour GJ, San Agustin JT, Follit JA, et al. Polycystin-2 localizes to kidney cilia and the ciliary 
level is elevated in orpk mice with polycystic kidney disease. Curr Biol. 2002; 12:R378–380. 
[PubMed: 12062067] 
Ong and Harris Page 18
Kidney Int. Author manuscript; available in PMC 2016 April 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
142. Lin F, Hiesberger T, Cordes K, et al. Kidney-specific inactivation of the KIF3A subunit of 
kinesin-II inhibits renal ciliogenesis and produces polycystic kidney disease. Proc Natl Acad Sci 
U S A. 2003; 100:5286–5291. [PubMed: 12672950] 
143. Masyuk TV, Huang BQ, Ward CJ, et al. Defects in cholangiocyte fibrocystin expression and 
ciliary structure in the PCK rat. Gastroenterology. 2003; 125:1303–1310. [PubMed: 14598246] 
144. Ong AC. Primary cilia and renal cysts: does length matter? Nephrology, dialysis, transplantation: 
official publication of the European Dialysis and Transplant Association - European Renal 
Association. 2013; 28:2661–2663. [PubMed: 23935132] 
145. Nachury MV, Loktev AV, Zhang Q, et al. A core complex of BBS proteins cooperates with the 
GTPase Rab8 to promote ciliary membrane biogenesis. Cell. 2007; 129:1201–1213. [PubMed: 
17574030] 
146. Garcia-Gonzalo FR, Reiter JF. Scoring a backstage pass: mechanisms of ciliogenesis and ciliary 
access. J Cell Biol. 2012; 197:697–709. [PubMed: 22689651] 
147. Praetorius HA, Spring KR. Bending the MDCK cell primary cilium increases intracellular 
calcium. J Membr Biol. 2001; 184:71–79. [PubMed: 11687880] 
148. Nauli SM, Alenghat FJ, Luo Y, et al. Polycystins 1 and 2 mediate mechanosensation in the 
primary cilium of kidney cells. Nat Genet. 2003; 33:129–137. [PubMed: 12514735] 
149. Xu C, Rossetti S, Jiang L, et al. Human ADPKD primary cyst epithelial cells with a novel, single 
codon deletion in the PKD1 gene exhibit defective ciliary polycystin localization and loss of 
flow-induced Ca2+ signaling. Am J Physiol Renal Physiol. 2007; 292:F930–945. [PubMed: 
17090781] 
150. Kottgen M, Buchholz B, Garcia-Gonzalez MA, et al. TRPP2 and TRPV4 form a polymodal 
sensory channel complex. J Cell Biol. 2008; 182:437–447. [PubMed: 18695040] 
151. McGrath J, Somlo S, Makova S, et al. Two populations of node monocilia initiate left-right 
asymmetry in the mouse. Cell. 2003; 114:61–73. [PubMed: 12859898] 
152. Field S, Riley KL, Grimes DT, et al. Pkd1l1 establishes left-right asymmetry and physically 
interacts with Pkd2. Development. 2011; 138:1131–1142. [PubMed: 21307093] 
153. Kamura K, Kobayashi D, Uehara Y, et al. Pkd1l1 complexes with Pkd2 on motile cilia and 
functions to establish the left-right axis. Development. 2011; 138:1121–1129. [PubMed: 
21307098] 
154. Pennekamp P, Karcher C, Fischer A, et al. The ion channel polycystin-2 is required for left-right 
axis determination in mice. Curr Biol. 2002; 12:938–943. [PubMed: 12062060] 
155. Karcher C, Fischer A, Schweickert A, et al. Lack of a laterality phenotype in Pkd1 knock-out 
embryos correlates with absence of polycystin-1 in nodal cilia. Differentiation; research in 
biological diversity. 2005; 73:425–432.
156. Delling M, DeCaen PG, Doerner JF, et al. Primary cilia are specialized calcium signalling 
organelles. Nature. 2013; 504:311–314. [PubMed: 24336288] 
157. DeCaen PG, Delling M, Vien TN, et al. Direct recording and molecular identification of the 
calcium channel of primary cilia. Nature. 2013; 504:315–318. [PubMed: 24336289] 
158. Choi YH, Suzuki A, Hajarnis S, et al. Polycystin-2 and phosphodiesterase 4C are components of 
a ciliary A-kinase anchoring protein complex that is disrupted in cystic kidney diseases. Proc 
Natl Acad Sci U S A. 2011; 108:10679–10684. [PubMed: 21670265] 
159. Raychowdhury MK, Ramos AJ, Zhang P, et al. Vasopressin receptor-mediated functional 
signaling pathway in primary cilia of renal epithelial cells. Am J Physiol Renal Physiol. 2009; 
296:F87–97. [PubMed: 18945824] 
160. Pisitkun T, Shen RF, Knepper MA. Identification and proteomic profiling of exosomes in human 
urine. Proc Natl Acad Sci U S A. 2004; 101:13368–13373. [PubMed: 15326289] 
161. Hogan MC, Manganelli L, Woollard JR, et al. Characterization of PKD protein-positive exosome-
like vesicles. J Am Soc Nephrol. 2009; 20:278–288. [PubMed: 19158352] 
162. Bakeberg JL, Tammachote R, Woollard JR, et al. Epitope-tagged Pkhd1 tracks the processing, 
secretion, and localization of fibrocystin. Journal of the American Society of Nephrology: JASN. 
2011; 22:2266–2277. [PubMed: 22021705] 
163. Fischer E, Legue E, Doyen A, et al. Defective planar cell polarity in polycystic kidney disease. 
Nat Genet. 2006; 38:21–23. [PubMed: 16341222] 
Ong and Harris Page 19
Kidney Int. Author manuscript; available in PMC 2016 April 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
164. Simons M, Gloy J, Ganner A, et al. Inversin, the gene product mutated in nephronophthisis type 
II, functions as a molecular switch between Wnt signaling pathways. Nat Genet. 2005; 37:537–
543. [PubMed: 15852005] 
165. Boca M, D’ Amato L, Distefano G, et al. Polycystin-1 induces cell migration by regulating 
phosphatidylinositol 3-kinase-dependent cytoskeletal rearrangements and GSK3beta-dependent 
cell cell mechanical adhesion. Mol Biol Cell. 2007; 18:4050–4061. [PubMed: 17671167] 
166. Luyten A, Su X, Gondela S, et al. Aberrant regulation of planar cell polarity in polycystic kidney 
disease. J Am Soc Nephrol. 2010; 21:1521–1532. [PubMed: 20705705] 
167. Nishio S, Tian X, Gallagher AR, et al. Loss of oriented cell division does not initiate cyst 
formation. J Am Soc Nephrol. 2010; 21:295–302. [PubMed: 19959710] 
168. Leightner AC, Hommerding CJ, Peng Y, et al. The Meckel syndrome protein meckelin 
(TMEM67) is a key regulator of cilia function but is not required for tissue planar polarity. Hum 
Mol Genet. 2013; 22:2024–2040. [PubMed: 23393159] 
169. Karner CM, Chirumamilla R, Aoki S, et al. Wnt9b signaling regulates planar cell polarity and 
kidney tubule morphogenesis. Nat Genet. 2009; 41:793–799. [PubMed: 19543268] 
170. Castelli M, Boca M, Chiaravalli M, et al. Polycystin-1 binds Par3/aPKC and controls convergent 
extension during renal tubular morphogenesis. Nat Commun. 2013; 4:2658. [PubMed: 24153433] 
171. Tran PV, Haycraft CJ, Besschetnova TY, et al. THM1 negatively modulates mouse sonic 
hedgehog signal transduction and affects retrograde intraflagellar transport in cilia. Nat Genet. 
2008; 40:403–410. [PubMed: 18327258] 
172. Tran PV, Talbott GC, Turbe-Doan A, et al. Downregulating hedgehog signaling reduces renal 
cystogenic potential of mouse models. J Am Soc Nephrol. 2014; 25:2201–2212. [PubMed: 
24700869] 
173. Senee V, Chelala C, Duchatelet S, et al. Mutations in GLIS3 are responsible for a rare syndrome 
with neonatal diabetes mellitus and congenital hypothyroidism. Nat Genet. 2006; 38:682–687. 
[PubMed: 16715098] 
174. Kang HS, Beak JY, Kim YS, et al. Glis3 is associated with primary cilia and Wwtr1/TAZ and 
implicated in polycystic kidney disease. Mol Cell Biol. 2009; 29:2556–2569. [PubMed: 
19273592] 
175. Chang MY, Parker E, Ibrahim S, et al. Haploinsufficiency of Pkd2 is associated with increased 
tubular cell proliferation and interstitial fibrosis in two murine Pkd2 models. Nephrol Dial 
Transplant. 2006; 21:2078–2084. [PubMed: 16720597] 
176. Li X, Luo Y, Starremans PG, et al. Polycystin-1 and polycystin-2 regulate the cell cycle through 
the helix-loop-helix inhibitor Id2. Nat Cell Biol. 2005; 7:1202–1212. [PubMed: 16311606] 
177. Battini L, Macip S, Fedorova E, et al. Loss of polycystin-1 causes centrosome amplification and 
genomic instability. Hum Mol Genet. 2008; 17:2819–2833. [PubMed: 18566106] 
178. Ma M, Tian X, Igarashi P, et al. Loss of cilia suppresses cyst growth in genetic models of 
autosomal dominant polycystic kidney disease. Nature genetics. 2013; 45:1004–1012. [PubMed: 
23892607] 
179. Sharif-Naeini R, Folgering JH, Bichet D, et al. Polycystin-1 and -2 dosage regulates pressure 
sensing. Cell. 2009; 139:587–596. [PubMed: 19879844] 
180. Peyronnet R, Sharif-Naeini R, Folgering JH, et al. Mechanoprotection by polycystins against 
apoptosis is mediated through the opening of stretch-activated K(2P) channels. Cell Rep. 2012; 
1:241–250. [PubMed: 22832196] 
181. Lee K, Boctor S, Barisoni LM, et al. Inactivation of Integrin-beta1 Prevents the Development of 
Polycystic Kidney Disease after the Loss of Polycystin-1. J Am Soc Nephrol. 2014
182. Silberberg M, Charron AJ, Bacallao R, et al. Mispolarization of Desmosomal Proteins and 
Altered Intercellular Adhesion in Autosomal Dominant Polycystic Kidney Disease. Am J Physiol 
Renal Physiol. 2005
183. Natoli TA, Gareski TC, Dackowski WR, et al. Pkd1 and Nek8 mutations affect cell-cell adhesion 
and cilia in cysts formed in kidney organ cultures. Am J Physiol Renal Physiol. 2008; 294:F73–
83. [PubMed: 17928412] 
Ong and Harris Page 20
Kidney Int. Author manuscript; available in PMC 2016 April 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
184. Charron AJ, Nakamura S, Bacallao R, et al. Compromised cytoarchitecture and polarized 
trafficking in autosomal dominant polycystic kidney disease cells. J Cell Biol. 2000; 149:111–
124. [PubMed: 10747091] 
185. Fogelgren B, Lin SY, Zuo X, et al. The exocyst protein Sec10 interacts with Polycystin-2 and 
knockdown causes PKD-phenotypes. PLoS Genet. 2011; 7:e1001361. [PubMed: 21490950] 
186. Battini L, Fedorova E, Macip S, et al. Stable knockdown of polycystin-1 confers integrin-
alpha2beta1-mediated anoikis resistance. J Am Soc Nephrol. 2006; 17:3049–3058. [PubMed: 
17005934] 
187. Sutton KA, Jungnickel MK, Ward CJ, et al. Functional characterization of PKDREJ, a male germ 
cell-restricted polycystin. J Cell Physiol. 2006; 209:493–500. [PubMed: 16883570] 
188. Ishimaru Y, Inada H, Kubota M, et al. Transient receptor potential family members PKD1L3 and 
PKD2L1 form a candidate sour taste receptor. Proc Natl Acad Sci U S A. 2006; 103:12569–
12574. [PubMed: 16891422] 
189. Mackenzie FE, Romero R, Williams D, et al. Upregulation of PKD1L2 provokes a complex 
neuromuscular disease in the mouse. Human molecular genetics. 2009; 18:3553–3566. [PubMed: 
19578180] 
190. Chen Y, Zhang Z, Lv XY, et al. Expression of Pkd2l2 in testis is implicated in spermatogenesis. 
Biol Pharm Bull. 2008; 31:1496–1500. [PubMed: 18670078] 
191. Hanaoka K, Qian F, Boletta A, et al. Co-assembly of polycystin-1 and -2 produces unique cation-
permeable currents. Nature. 2000; 408:990–994. [PubMed: 11140688] 
192. Inoue Y, Sohara E, Kobayashi K, et al. Aberrant glycosylation and localization of polycystin-1 
cause polycystic kidney in an AQP11 knockout model. J Am Soc Nephrol. 2014; 25:2789–2799. 
[PubMed: 24854278] 
193. Cogswell C, Price SJ, Hou X, et al. Positional cloning of jcpk/bpk locus of the mouse. Mamm 
Genome. 2003; 14:242–249. [PubMed: 12682776] 
194. Wodarczyk C, Distefano G, Rowe I, et al. Nephrocystin-1 forms a complex with polycystin-1 via 
a polyproline motif/SH3 domain interaction and regulates the apoptotic response in mammals. 
PloS one. 2010; 5:e12719. [PubMed: 20856870] 
195. Su X, Driscoll K, Yao G, et al. Bardet-Biedl syndrome proteins 1 and 3 regulate the ciliary 
trafficking of polycystic kidney disease 1 protein. Hum Mol Genet. 2014; 23:5441–5451. 
[PubMed: 24939912] 
Ong and Harris Page 21
Kidney Int. Author manuscript; available in PMC 2016 April 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 1. Dosage dependent disease mechanism in PKD1
The level of functional PC1 (bottom) directly influences the renal phenotype with a ~50% 
reduction (haploinsufficiency due to a single inactivating allele) associated with adult onset 
disease and no PC1 incompatible with life. Incompletely penetrant (hypomorphic) PC1 
alleles of different strengths and combinations can significantly influence the renal 
phenotype. The PC1 allele p.Y528C has a phenotype similar to PKD267 while p.R3277C 
can result in a few cysts, adult onset disease or early onset disease depending on the in trans 
combination32, 36. Additional mutations/variants at the disease locus and elsewhere (somatic 
and germline), along with chance and environmental factors influence the disease course by 
determining the frequency of cyst development.
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Figure 2. Genetic and biochemical interactions between known cystoproteins
Genetic and/or biochemical interactions are shown as solid lines. The murine cystoproteins 
shaded in grey (Aqp11, Bicc1, Taz) represent those where a human PKD phenotype has not 
yet been reported123, 192, 193. Biochemical interactions between PC1 and NPHP1 and BBS1 
have been reported194, 195.
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Figure 3. Structure and functions of PC1 and related polycystin-like proteins, plus PC2
The Key shows the different domains and other motifs found in these proteins. PC2 is shown 
complexed with PC1 via PC2 CC2 and the PC1 coiled coil region. A high degree of 
similarity between PC1 paralogs is found in the transmembrane regions but with more 
variation in the N-terminal ectodomains and the cytoplasmic tails. The structure of PC2L1 
and PC2L2 are similar to PC2 but PC2L2 does not have an EF-hand.
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Figure 4. Models of the biosynthesis, maturation and trafficking of the polycystin complex
PC1 (red) binds to PC2 (blue) shown as a putative dimer in the ER prior to undergoing GPS 
cleavage. At this stage, both proteins are expressed as EndoH-sensitive glycoforms (empty 
circles). EndoH-resistance (filled circles) is acquired with passage through the trans-Golgi 
with a small pool of an EndoH-resistant complex detectable in primary cilia. An alternative 
model proposes that EndoH-sensitive PC2 exits the cis-Golgi and traffics independently of 
PC1 which undergoes normal Golgi maturation, acquiring Endo H-resistance. The broken 
lines indicate other regulatory pathways which could determine the levels of both proteins, 
complex formation and subcellular localisation.
Ong and Harris Page 25
Kidney Int. Author manuscript; available in PMC 2016 April 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
